Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Oric Pharmaceuticals (ORIC) R&D In Process (2020 - 2022)

Oric Pharmaceuticals filings provide 2 years of R&D In Process readings, the most recent being $5.0 million for Q3 2022.

  • Quarterly R&D In Process changed N/A to $5.0 million in Q3 2022 from the year-ago period, while the trailing twelve-month figure was $5.0 million through Dec 2023, changed 0.0% year-over-year, with the annual reading at $5.0 million for FY2022, N/A changed from the prior year.
  • R&D In Process hit $5.0 million in Q3 2022 for Oric Pharmaceuticals, down from $11.9 million in the prior quarter.
  • Across five years, R&D In Process topped out at $13.0 million in Q3 2020 and bottomed at $5.0 million in Q3 2022.